HBC Hofseth Biocare

Hofseth Biocare ASA: SECURES DISTRIBUTION WITH A GLOBAL RETAILER GIANT IN THE UK, SPAIN, ICELAND, AND ONLINE FOR BRILLIANT SALMON OILâ„¢ FOR PETS

Hofseth Biocare ASA: SECURES DISTRIBUTION WITH A GLOBAL RETAILER GIANT IN THE UK, SPAIN, ICELAND, AND ONLINE FOR BRILLIANT SALMON OIL™ FOR PETS

Hofseth BioCare ASA (“HBC”) pet care product Brilliant Salmon Oil™, a food and health supplement for dogs and cats, is now available in outlets across the UK, Spain, Iceland and online.

This retail distribution agreement with a global leading club store is an important milestone for HBC in its efforts for global distribution of Brilliant Salmon Oil™. The launch has started very successfully, and in-store incentive promotions will start at the end of the month to raise even more awareness. 

Kai Morten Thuen, Hofseth BioCare ASA’s Head of Sales & Marketing states, “This is an honor and great recognition for our company. We are thrilled to enter this retail agreement with one of the most well-renowned global retailers, known for their rigorous quality standards. It further accelerates our growth strategy for our pet care market flagship product, Brilliant Salmon Oil.”

Furthermore, in the last three months, HBC has signed up seven more distributors in the US and Canada, covering most of North America.  Brilliant Salmon Oil™ first entered a US store in April of this year and will be available in over 1,000 stores by the end of September. The speed of this success, despite a COVID-19 market slowdown, is seen as very encouraging and outpaces our expectations. 

About Brilliant Salmon Oil:

Brilliant Salmon Oil by Hofseth BioCare is produced in Norway using the purest process possible. Due to the unique patented extraction process – without boiling or pressing the oil – all the natural nutrients in the Atlantic Salmon are preserved. The whole process happening within hours, result in the purest and most transparent oil, completely free of additives. Brilliant contributes to shinier coat, softer paws, as well as helping to prevent cardiovascular disease. 

For further information, please contact:

Kai Morten Thuen, Head of Sales and Marketing at Hofseth BioCare ASA

Phone:

E-mail:

James Berger, Head of Investor Relations & Strategy at Hofseth BioCare ASA

Phone:

E-mail:

About Hofseth BioCare ASA:

HBC is a Norwegian biotech company that develops high-value ingredients and finished products. The ingredients are in various stages of discovery and preclinical development in collaboration with multiple clinics and university research labs in several countries. Lead preclinical and clinical candidates are in development toward treatment for iron-deficiency anaemia, Gastro-Intestinal Inflammation (NEC/IBS/UC), prediabetes, age-related sarcopenia and osteoarthritis.

The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, HBC can preserve the quality of lipids, proteins and calcium from fresh salmon off-cuts. Hofseth BioCare's headquarters are in Ålesund, Norway with branches in Oslo, London, Zürich, Chicago, Menlo Park and Tokyo.

HBC is listed on Oslo Stock Exchange Axess list with ticker "HBC". More information about Hofseth BioCare at hofsethbiocare.com and facebook.com/hofsethbiocare



This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act

EN
27/08/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Hofseth Biocare

 PRESS RELEASE

Hofseth Biocare ASA: AECORBIO SECURES A FURTHER $1.5M AT A $30M VALUAT...

Hofseth Biocare ASA: AECORBIO SECURES A FURTHER $1.5M AT A $30M VALUATION FOR ONGOING FT-002A PEPTIDE DEVELOPMENT IN PROSTATE CANCER AecorBio Inc., formerly known as HBC Immunology Inc, has successfully completed a further equity financing round of $1.5m from existing and new investors at a company valuation of $30 million. This funding will enable AecorBio to complete the investigational work of its lead peptide candidate FT-002a, in advanced prostate cancer, to enable an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in 2026. Filing the IND wil...

 PRESS RELEASE

Hofseth Biocare ASA: ProGo, the world’s first consumer health GLP-1 & ...

Hofseth Biocare ASA: ProGo, the world’s first consumer health GLP-1 & GIP receptor agonist with muscle mass protection via inhibition of Myostatin and Activin A pathways HBC has today released a whitepaper demonstrating how its bioactive peptide ingredient ProGo® uniquely provides complete GLP-1 support. To maximize the effect of GLP-1 therapy, lean muscle mass needs to be protected to optimize the benefits of weight loss and support a healthy metabolism. ProGo®️ addresses these needs through its unique triple action properties: highly absorbable protein with a complete amino acid profi...

 PRESS RELEASE

Hofseth Biocare ASA: HBC onboards former Head of Nestle Health Science...

Hofseth Biocare ASA: HBC onboards former Head of Nestle Health Science Asia, Oceania, Middle East and Africa Region, Paul Bruhn HBC is delighted to announce the appointment of Paul Bruhn as Head of New Business Development. Mr Bruhn has over 25 years’ experience in healthcare and the medical nutrition space spanning Novartis Medical Nutrition and Nestle Health Science. He has been leading businesses across multiple geographies including Japan, Korea, India, Middle East, Singapore, Canada, Switzerland and Australia and hence has an excellent overlap with corporates focused on developing the...

 PRESS RELEASE

Hofseth Biocare ASA: SECOND QUARTER 2025 FINANCIAL REPORT

Hofseth Biocare ASA: SECOND QUARTER 2025 FINANCIAL REPORT HBC recorded total operating revenues of NOK 68.4 million in the second quarter of 2025, compared to NOK 80.4 million in the same period last year. Net operating revenues were NOK 67.8 million, compared to NOK 72.2 million in the same quarter last year. Total operating revenue for the first six months of 2025 was NOK 129.3 million (NOK 132.8 million). EBITDA for the quarter was negative NOK 5.4 million, compared to NOK -2.0 million in Q2 2024. The first six months was negative NOK 25.3 million (NOK-18.2 million) The Operational EBIT...

 PRESS RELEASE

Hofseth Biocare ASA: HBC’s ProGo® has won Ingredient of the Year for H...

Hofseth Biocare ASA: HBC’s ProGo® has won Ingredient of the Year for Healthy Aging at the prestigious Nutraingredients USA awards ceremony in Chicago According to the judges, the winning factors placing ProGo® well ahead of the competition are its unique ability to activate GLP-1 and GIP receptors, coupled with its unrivalled sustainability credentials including Upcycled Certified by WFCF (Where Food Comes From). Most significantly, these benefits are supported and evidenced through two clinical studies demonstrating weight loss with ProGo®. ProGo® Bioactive Peptides optimize the metabolis...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch